Takeda’s Ninlaro is a treatment for patients with multiple myeloma who have had at least one prior therapy.
Specialty Pharmacy News
The average annual cost of a specialty medication used on a chronic basis exceeded $53,000 in 2013, which is more than the median U.S. household income, AARP noted.
The healthcare logistics industry has seen significant improvements in product security and regulatory compliance across the supply chain.
AxelaCare enhances OptumRx’s ability to deliver care to the growing number of consumers managing complex conditions through at-home infusions.
Tagrisso is an EGFR-tyrosine kinase inhibitor, a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations, and T790M, the genetic mutation responsible for EGFR-TKI treatment resistance in up to approximately two-thirds of cases of EGFRm advanced NSCLC.
The moves are part of a strategic move to align efforts for internal improvement, the specialty pharmacy operator said.
A new drug has been approved that, in conjunction with vemurafenib, is meant to treat metastatic melanoma that can't be removed through surgery with a certain gene mutation.
Consider this: 1-in-5 hospital patients end up back in the hospital within 30 days of their discharge. And the biggest factors pulling them back all have to do with medications — either through medication errors, nonadherence or adverse drug events.
The combination of Cotellic with Zelboraf helps patients with previously untreated BRAF V600 mutation-positive advanced melanoma live a median of one year (12.3 months) without their disease worsening, compared to 7.2 months with Zelboraf alone.